What is Dynavax Technologies?
Founded in 1996 and headquartered in Emeryville, California, Dynavax Technologies Corporation is dedicated to harnessing the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's pipeline includes product candidates under investigation for various cancer indications, a vaccine for hepatitis B prevention, and a disease-modifying therapy for asthma. Dynavax's strategic focus on immune system modulation positions it within the competitive biotechnology and pharmaceutical landscape, aiming to deliver novel treatments for significant unmet medical needs.
How much funding has Dynavax Technologies raised?
Dynavax Technologies has raised a total of $293.9M across 5 funding rounds:
Stock Offering
$45M
Stock Offering
$20.1M
Stock Offering
$43.9M
Stock Offering
$85.9M
Debt
$99M
Stock Issuance/Offering (2004): $45M, investors not publicly disclosed
Stock Issuance/Offering (2010): $20.1M, investors not publicly disclosed
Stock Issuance/Offering (2010): $43.9M, investors not publicly disclosed
Stock Issuance/Offering (2013): $85.9M, investors not publicly disclosed
Debt (2021): $99M backed by Coalition for Epidemic Preparedness Innovations
Key Investors in Dynavax Technologies
Coalition for Epidemic Preparedness Innovations
Coalition for Epidemic Preparedness Innovations (CEPI) is a global initiative focused on funding and coordinating the development of vaccines against emerging infectious diseases. Their investment in Dynavax likely aligns with CEPI's mission to prevent future epidemics through vaccine advancement.
What's next for Dynavax Technologies?
With substantial enterprise-level backing and a recent strategic investment, Dynavax Technologies is poised for accelerated development and potential commercialization of its immunotherapy candidates. The company's focus on TLR stimulation technology suggests a strategic pathway toward expanding its portfolio and addressing critical therapeutic areas, including oncology and infectious diseases. Future growth will likely involve advancing clinical trials, securing regulatory approvals, and potentially forging strategic partnerships to maximize the reach and impact of its innovative treatments.
See full Dynavax Technologies company page
